What are the adverse reactions of Tazemetostat?

In clinical studies of Tazemetostat in the treatment of epithelioid sarcoma, the most common (≥20%) adverse reactions included pain, fatigue, nausea, decreased appetite, vomiting, constipation, anemia, and lymphopenia. Serious adverse reactions occurred in 37% of patients, including bleeding, pleural effusion, skin infection, dyspnea, pain, and respiratory distress. In clinical studies for the treatment of follicular lymphoma, the most common (≥20%) adverse reactions include fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, abdominal pain, lymphopenia, hyperglycemia, leukopenia, neutropenia, thrombocytopenia, and anemia.

In clinical studies of tazerestat treatment, warnings and precautions such as secondary malignant tumors and embryo-fetal toxicity have also emerged. Tazerestat can render some hormonal contraceptives ineffective, so females of reproductive potential are advised to use an effective non-hormonal method of contraception during treatment and for 6 months after the last dose. Because of its mechanism of action and the potential risk of serious adverse reactions in breastfed children, women are advised not to breastfeed during treatment with tazerestat and for one week after the last dose.

The original drug of tazerestat is not yet available in the domestic market and is therefore not included in medical insurance. Tazerestat US version of the original drug, specification200mg*240 tablets, which is marketed overseas, may cost around 200,000 yuan per bottle (the price may fluctuate due to exchange rates), which is very expensive. At present, there are no generic drugs of tazerestat produced and launched. For more drug information and specific prices, please consult the medical consultant of the drug.